Background: p53 mutation is the most common genetic alteration in cancers and influences clinical progression. Ki-67 protein is a cellular marker for proliferation in cancer or premalignant lesion. The aim of this study is to investigate whether p53 and Ki-67 measurements in gastric tumors would be helpful in determining treatment strategy. Methods: Immunohistochemical staining using monoclonal antibodies to p53 and Ki-67 was performed on specimens from 29 gastric adenomas (GA) by endoscopic submucosal dissection (ESD) and 240 gastric cancers (GC) by ESD or gastrectomy. Tumor cells with nuclear p53 and Ki-67 protein expression were arbitrarily graded into four groups: < 10 % = negative, 10-30 % = 1+, 30-60 % = 2+, and > 60 % = 3+. Results: The mean tumor sizes in the GA and GC groups were 17.3 ± 11.4 mm and 32.0 ± 20.9 mm respectively (P < 0.001). p53 positivity was not different between the GA and GC groups (P = 0.149), but Ki-67 positivity was significantly different between the 2 groups (P = 0.001). In addition, Ki-67 positivity tended to be increased as the pathologic progression changed from adenoma to cancer. Conclusions: Ki-67 positivity grade seems to be correlated with malignancy potential. Even if endoscopic biopsy showed low grade dysplasia, in lesions with high Ki-67 positivity, it is better to consider active ESD rather than just long-term follow up.
INTRODUCTION INTRODUCTION
The stomach adenoma is a common benign tumor originating from the gastric glandular epithelium, accounting for 10% of all stomach polyps (1) . Gastric adenoma is also considered a precancerous lesion (2, 3) . The risk factors for malignancy in gastric adenomas are large tumor size and high-grade dysplasia (4) (5) (6) . However, these factors are not sufficient to predict the cancerous progression of each adenoma.
The p53 tumor suppressor gene functions by regulating cell proliferation through control of the G1 arrest checkpoint in the cell cycle (7, 8) . Mutation in the p53 gene is one of the most common genetic lesions associated with gastric cancer, and some studies have reported that the expression of p 53 is related to bad prognosis (9) (10) (11) (12) (13) (14) .
Ki-67 is related to cell proliferation (15, 16) , and advanced gastric cancer (AGC) patients have higher Ki-67 labeling rates than early gastric cancer patients. Also, Ki-67 labeling index was significantly higher in gastric cancer patients with lymph node metastasis (17, 18) .
Although there are some qualitative studies for p53 and Ki-67 expression using immunohistochemistry (IHC) in gastric adenoma and gastric cancer, there is no report on the quantification of expression intensity. We wanted to know whether immunostaining grading of p53 or Ki-67 of tumor cells is different or not between gastric cancer and gastric low-grade adenoma. We divided patients with gastric adenoma or gastric cancer who were undergoing ESD or gastrectomy into 4 groups, depending on the expression proportion of p53 and Ki-67 by using IHC, and investigated whether this semi-quantified expression index for p53 and Ki-67 are possible indicators with regard to the prognosis of gastric adenoma.
METHODS METHODS

Patients
We analyzed p53 and Ki-67 expression in the tumor tissue of 29 gastric adenoma with low-grade dysplasia patients who were treated by endoscopic submucosal dissection (GA-LGD group) and 240 gastric cancer patients who were treated by endoscopic submucosal dissection or gastrectomy (GC group) at Kangnam Sacred Heart Hospital, Hallym University Sacred Heart Hospital of Hallym University, and Eulgi University Hospital from January 2009 to December 2016. The ethics committee of Hallym University Sacred Heart Hospital approved the research protocol and received informed consent from each patient (Clinical trial registration No. KCT 0002314).
Methods
Paraffin-embedded samples were cut into fourmicrometer sections and mounted on poly-L-lysine coated slides. The specimens were processed by an automated IHC system (BondTM System, Leica Microsystems, Bannockburn, IL, U.S.A.) using monoclonal antibodies against p53 (DO-7, mouse monoclonal, Dako, Glostrup, Denmark, dilution 1: 3000) and Ki-67 (MIB-5, mouse monoclonal, Dako, dilution 1: 250). The proportion of tumor cells with nuclear p53 protein immunostaining was arbitrarily graded into four groups: <10%=negative, 10-30%=1+, 30-60%=2+, and >60%=3+ of the total tumour cell population per section ( fig. 1 ). Four sections from each tumor were scored. A tumor was scored as p53 positive when at least 10% of the tumor cells showed nuclear p53 protein accumulation. The Ki-67 labeling index was obtained by using light microscopy at 400 x magnification and the ratio was calculated as the percentage of 500 tumor cells, and also semi-quantitatively graded from negative to 3+ in the same manner ( fig. 2) . One pathologist in each hospital evaluated specimens after consensus meeting.
Statistical analysis
The Mann-Whitney U test was used to compare age and lesion size. When comparing IHC staining between gastric cancer and gastric adenoma, linear by linear associations and Pearsons' chi-square test were performed. Values were considered significant at p<0.05. All analysis was performed using PASW Statistics for Windows, Version 18.0 (SPSS, Inc., Chicago, IL).
RESULTS RESULTS
There were 29 cases of gastric adenoma with low grade dysplasia and 240 cases with advanced gastric cancer (AGC) and early gastric cancer (EGC). The mean age was 63.5 ± 11.8 years and the mean tumor size was 30.4 ± 20.6 mm. Comparing the two groups, the mean tumor size was 17.3 ± 11.4 mm in the GA-LGD group and 32.0 ± 20.9 mm in the GC group while the mean age was 64.7 ± 9.8 years old in the GA-LGD group and 63.4 ± 12.1 years old in the GC group. There was no significant difference between the two groups when comparing these parameters. The clinicopathologic characteristics of the GA-LGD and GC groups are shown in table 1.
In the GA-LGD group, the expression index for p53 was as follows: negative, 10.3%; 1+, 31.0%; 2+, 55.2%; and 3+, 3.4%. In the GC group, the expression index was: negative, 32.5%; 1+, 10.0%; 2+, 56.7%; and 3+, 0.8% (table 2). The semi-quantified positivity of p53 was not significantly different between the two groups (p=0.149). For the GA-LGD group, the expression index of Ki-67 was as follows: negative, 0.0%; 1+, 13.8%; 2+, 27.6%; and 3+, 58.6%. For the GC group, the expression index was: negative, 0.4%; 1+, 5.4%; 2+, 7.1%; and 3+, 87.1%. The semiquantified positivity for Ki-67 was significantly higher in the GC group (p=0.001). In addition, the semiquantified positivity for Ki-67 increased as the tumor changed from adenoma to cancer (table 2, fig. 3 ).
The semi-quantified positivity of p53 was not The semi-quantified positivity of p53 was significantly different according to T stage (p=0.047). The semi-quantified positivity for Ki-67 was significantly different according to T stage (p=0.013). The over 2+ positivity for p53 increased as the tumor changed from T0 to T4. 3+ positivity for Ki-67 increased as the tumor changed from T0 to T4 (table 4) .
The semi-quantified positivity of p53 was significantly different according to lymph node status (p=0.047). The semi-quantified positivity for Ki-67 was significantly different according to lymph node status (p=0.027). The over 2+ positivity for p53 increased as the tumor changed from N0 to N3. 3+ positivity for Ki-67 increased as the tumor changed from N0 to N3 (table 5). 
DISCUSSION DISCUSSION
The gastric adenoma undergoes malignant transformation that gradually changes from low-grade to highgrade dysplasia. Low-grade dysplastic gastric adenomas evolved into stomach cancer after an average of 48 months (range 21-85) of follow-up observation (19) . High-grade dysplastic gastric adenomas progress to cancer at 60-70% and progress to stomach cancer at 2-6% per year (5, 19, 20) . The p53 tumor suppressor gene is located on chromosome 17p and regulates cell cycle, DNA repair and synthesis, and apoptosis (21, 22) . The production of p53 increases with intracellular damage or DNA damage, and p53 induces cell cycle arrest at the G1 / S-junction (7). The loss of p53 function is related to the progression of the tumor by allowing cells with damaged DNA to continue to multiply (23) . In some studies, p53 expression in stomach cancer has been reported to be bad prognosis (9) (10) (11) (12) (13) (14) , but other reports have shown that p53 expression has no effect on clinical results (24) (25) (26) . The reasons for these conflicting results are unclear. However, recent studies have shown a correlation between p53 expression and higher proliferative activity; suggesting that changes in the p53 gene promote cell proliferation and uncontrolled cell division (22, 27, 28) . A comparison of stomach cancer and gastric adenoma has shown that stomach cancer has higher incidence of p53 than gastric adenoma (29, 30) . Our results do not show statistically significant differences on the expression of p53 between gastric adenoma and gastric cancer. Moreover, Oiwa et al. (31) reported that only 20% of EGC patients had p53 overexpression. Uchino et al. (32) reported the accumulation of p53 protein was observed in 15 (37%) of 41 cohesive type EGC patients and was not seen in 18 patients with signet ring cell type EGC. In this study, the semi-quantified positivity of p53 and Ki-67 were not significantly different according to the tumor pathology (p=0.777, p=0.101, respectively). Ki-67 monoclonal antibody reacts with a nuclear antigen that exists in proliferating cells throughout the cell cycle (late G1, S-, G2, and M-phase) but not in G0 phase cells (33) . The Ki-67 marker index was higher in patients with AGC than in EGC patients and was reported to be a useful predictor of lymph node metastasis and invasion depth (17) . In this study, the semi-quantified positivity of p53 and Ki-67 were significantly different according to T stage (p=0.047, p=0.013, respectively) and increased as the tumor changed from T0 to T4. The semi-quantified positivity of p53 and Ki-67 were significantly different according to lymph node status (p=0.047, p=0.027, respectively) and increased as the tumor changed from N0 to N3. The semi-quantified positivity of p53 and Ki-67 were significantly different according to lymph node status (p=0.047, p=0.027, respectively) and increased as the tumor changed from N0 to N3. The semi-quantified positivity of p53 and Ki-67 were significantly different according to stage (p=0.009, p=0.005, respectively) and increased as the tumor changed from stage 0 to stage 4. In another study, p53 and Ki-67 expression were related to response to chemotherapy (33) (34) (35) . Additionally, our study shows that the accumulation intensity of the Ki-67 protein tends to be increased as tumors progress from gastric adenoma to gastric cancer. The results of this study seem to be helpful in determining whether Ki-67 IHC analysis is help in the decision of ESD in gastric adenoma with low grade dysplasia. A limitation of this study is the lack of information regarding the follow-up of patients with gastric adenoma with low-grade dysplasia, because this is a pilot study. In the future, a well-designed long-term follow-up study is needed to estimate the effect of Ki-67 on low-grade gastric adenoma.
CONCLUSIONS CONCLUSIONS
Ki-67 positivity grade seems to be correlated with malignancy potential. Even if endoscopic biopsy showed low grade dysplasia, in lesions with high Ki-67 positivity, it is better to consider active ESD rather than just long-term follow up.
